)
DUPIXENT SIGNIFICANTLY REDUCED
COPD EXACERBATIONS1-3,a
When added to standard of care,
DUPIXENT significantly reduced the
annualized rate of moderate or
severe exacerbations
Annualized rate of moderate or severe
COPD exacerbations at Week 52
(primary endpoint)
PATIENTS WITH A HISTORY OF ASTHMA WERE EXCLUDED
FROM THE BOREAS AND NOTUS TRIALS2,3
Standard of care was triple inhaled therapy (LAMA+LABA+ICS).1,4
aModerate exacerbations were defined as exacerbations that resulted in treatment with a systemic glucocorticoid, an antibiotic agent, or both. Severe exacerbations were defined as exacerbations that led to hospitalization or an emergency medical care visit or that resulted in death.1
bRate ratio vs placebo: 0.71 (95% CI: 0.58, 0.86).1
cRate ratio vs placebo: 0.66 (95% CI: 0.54, 0.82).1
COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; SOC, standard of care.
DUPIXENT SHOWED IMPROVEMENT IN LUNG FUNCTION1
Lung function improvement sustained through Week 52
Post‑bronchodilator FEV1
Change in post‑bronchodilator FEV1 from baseline at Week 12 and Week 52 (ITT population; secondary endpoint)1,2
Patients administered DUPIXENT + SOC saw numerical improvement in post‑bronchodilator FEV1 of 134 mL at Week 12 (n=470) and 127 mL at Week 52 (n=362), compared with 67 mL at Week 12 (n=465) and 59 mL at Week 52 (n=359) in patients receiving placebo + SOC (LSM change from baseline, ITT population)1
Post-bronchodilator lung function results are descriptive. Definitive conclusions cannot be made.
Pre‑bronchodilator FEV1
Significant improvements of similar magnitude were observed in change from baseline in pre-
bronchodilator
FEV1 at Weeks 12 and 52 in subjects treated with DUPIXENT compared to placebo
across the BOREAS and NOTUS trials.1
DUPIXENT IMPROVED COPD
PATIENTS’ DAILY QUALITY OF LIFE1,2
Improvement as measured by SGRQ5
of patients reported a clinically
meaningful (≥4-point)
improvement at
Week 52
with DUPIXENT vs
43% for placebo
(N=939; OR: 1.44; 95% CI: 1.10,
1.89; P=0.009)1,2
51% responder rate at Week 52
for subjects treated with
DUPIXENT vs 47% for
placebo
(N=721;
OR: 1.16; 95% CI: 0.86,
1.58)1,3
NOTUS results are descriptive. Definitive conclusions cannot be made.
The sgrq measures the
qualitative impact of
copd2,5
SGRQ is a disease-specific
instrument designed to measure
impact on overall
health, daily life,
and
perceived well-being in
patients with COPD
Symptoms
Cough, sputum
production,
breathlessness,
and
wheezing
Activity
Disruption of daily
physical activity
Impacts
Disturbance to
psychosocial function
In NOTUS, patients receiving DUPIXENT + SOC (n=362) experienced -9.8
reduction in total SGRQ score vs
-6.4 with placebo + SOC (n=359) (LSM
difference: -3.4 [95% CI: -5.8,
-0.9]).4
NOTUS results are descriptive. Definitive conclusions cannot be made.
Standard of care was triple inhaled therapy (LAMA+LABA+ICS).1,4
DUPIXENT REDUCED
SGRQ SCORES–LOWER SGRQ
SCORES INDICATE IMPROVED
QUALITY OF
LIFE1,3
Standard of care was triple inhaled
therapy
(LAMA+LABA+ICS).1,4
ICS, inhaled corticosteroids; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; LSM, least squares mean; OR, odds ratio; SGRQ, St George's Respiratory Questionnaire; SOC, standard of care.
Explore study designs and safety data
Learn more about dosage and administration options for patients on DUPIXENT
FREQUENTLY ASKED QUESTIONS
In BOREAS, a 158 mL improvement from baseline in post‑bronchodilator FEV1 was seen at Week 12 with DUPIXENT SC 300 mg Q2W + SOC (n=468) vs 84 mL with placebo SC Q2W + SOC (n=471) (ITT population, secondary endpoint).1,2
In NOTUS, patients experienced a 134 mL improvement in post‑bronchodilator FEV1 lung function with DUPIXENT SC 300 mg Q2W + SOC (n=470) vs 67 mL with placebo SC Q2W + SOC (n=465) at Week 12 (LSM change from baseline, ITT population).1
Post-bronchodilator lung function results are descriptive. Definitive conclusions cannot be made.
Standard of care was triple inhaled therapy (LAMA+LABA+ICS).1,4
FEV1, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; ITT, intention-to-treat; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; LSM, least squares mean; Q2W, once every 2 weeks; SC, subcutaneous; SOC, standard of care.
EXPLORE THE LUNG FUNCTION DATA Discover THE FULL STUDY DESIGNSPatients in the BOREAS trial experienced sustained breathing relief at Week 52: a 138 mL improvement from baseline in post‑bronchodilator FEV1 with DUPIXENT SC 300 mg Q2W + SOC (n=468) vs 58 mL with placebo + SC Q2W SOC (n=471) (ITT population; secondary endpoint).1
Patients in the NOTUS trial experienced sustained breathing relief at Week 52: a 127 mL improvement from baseline in post‑bronchodilator FEV1 with DUPIXENT SC 300 mg Q2W + SOC (n=362) vs 59 mL with placebo + SC Q2W SOC (n=359) (LSM change from baseline, ITT population).1
Post-bronchodilator lung function results are descriptive. Definitive conclusions cannot be made.
Standard of care was triple inhaled therapy (LAMA+LABA+ICS).1,4
FEV1, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; ITT, intention-to-treat; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; Q2W, once every 2 weeks; SC, subcutaneous; SOC, standard of care.
Discover THE FULL STUDY DESIGNSIn the NOTUS trial, the annualized rate of moderate or severe COPD exacerbations declined by 34% in patients receiving DUPIXENT SC 300 mg Q2W + SOC (n=470) vs placebo SC Q2W + SOC (n=465) over 52 weeks (rate ratio: 0.66 [95% CI: 0.54, 0.82]; P<0.001).1-3
In the BOREAS trial, patients experienced a 30% reduction in the annualized rate of moderate or severe exacerbations at Week 52 with DUPIXENT 300 mg Q2W + SOC (n=468) vs placebo SC Q2W + SOC (n=471) (rate ratio: 0.71 [95% CI: 0.58, 0.86]; P<0.001).1-3
Standard of care was triple inhaled therapy (LAMA+LABA+ICS).1,4
Moderate exacerbations were defined as exacerbations that resulted in treatment with a systemic glucocorticoid, an antibiotic agent, or both. Severe exacerbations were defined as exacerbations that led to hospitalization or an emergency medical care visit or that resulted in death.1
COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; Q2W, once every 2 weeks; SC, subcutaneous; SOC, standard of care.
Discover THE FULL STUDY DESIGNSIn the BOREAS trial, patients receiving DUPIXENT + SOC (n=468) saw a 9.7-point improvement in SGRQ total score at Week 52 vs a 6.4-point improvement in patients receiving placebo + SOC (n=471; LSM difference: -3.4 [95% CI: -5.5, -1.3]; P=0.002). In NOTUS, patients receiving DUPIXENT + SOC (n=362) experienced 9.8-point improvement in total SGRQ score vs 6.4 improvement with placebo + SOC (n=359) (LSM difference: -3.4 [95% CI: -5.8, -0.9]).1-3
The BOREAS trial showed a 51% SGRQ responder rate at Week 52 for subjects treated with DUPIXENT vs 43% for placebo (N=939; OR: 1.44; 95% CI: 1.10, 1.89; P=0.009). The NOTUS trial showed a 51% responder rate at Week 52 for subjects treated with DUPIXENT vs 47% for placebo (N=721; OR: 1.16; 95% CI: 0.86, 1.58).1-3
NOTUS results are descriptive. Definitive conclusions cannot be made.
St George's Respiratory Questionnaire (SGRQ) total score is a patient self-measure of cough, sputum production, breathlessness, and wheezing, as well as disturbances to daily physical activity and psychosocial function. The SGRQ is a 50-item questionnaire designed to measure and quantify health status in adult patients with chronic airflow limitation. Higher score indicates greater disease severity.2,5
COPD, chronic obstructive pulmonary disease; LSM, least squares mean; SOC, standard of care.
EXPLORE ADDITIONAL QUALITY-OF-LIFE DATA